BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 32329889)

  • 21. The case for a medication first approach to the treatment of opioid use disorder.
    Winograd RP; Presnall N; Stringfellow E; Wood C; Horn P; Duello A; Green L; Rudder T
    Am J Drug Alcohol Abuse; 2019; 45(4):333-340. PubMed ID: 31084515
    [No Abstract]   [Full Text] [Related]  

  • 22. Diagnosis and Treatment of Opioid Use Disorder in 2020.
    Wakeman SE
    JAMA; 2020 May; 323(20):2082-2083. PubMed ID: 32329798
    [No Abstract]   [Full Text] [Related]  

  • 23. Buprenorphine for Persons on Waiting Lists for Treatment for Opioid Dependence.
    Yan K
    N Engl J Med; 2017 Mar; 376(10):1000. PubMed ID: 28276662
    [No Abstract]   [Full Text] [Related]  

  • 24. Buprenorphine for Persons on Waiting Lists for Treatment for Opioid Dependence.
    Sigmon SC; Schwartz RP; Higgins ST
    N Engl J Med; 2017 Mar; 376(10):1000-1001. PubMed ID: 28273017
    [No Abstract]   [Full Text] [Related]  

  • 25. Medication-Assisted Treatment for Opioid-Use Disorder.
    Oesterle TS; Thusius NJ; Rummans TA; Gold MS
    Mayo Clin Proc; 2019 Oct; 94(10):2072-2086. PubMed ID: 31543255
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rapid transition from methadone to buprenorphine using naltrexone-induced withdrawal: A case report.
    Ward HB; Barnett BS; Suzuki J
    Subst Abus; 2019; 40(2):140-145. PubMed ID: 30888254
    [No Abstract]   [Full Text] [Related]  

  • 27. A Comparison of Medication-Assisted Treatment Options for Opioid Addiction: A Review of the Literature.
    Spayde-Baker A; Patek J
    J Addict Nurs; 2023 Oct-Dec 01; 34(4):E189-E194. PubMed ID: 34224485
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recent Advances in the Treatment of Opioid Use Disorder.
    Kuppalli S; Seth R; Orhurhu V; Urits I; Kaye AD; Hunter C; Gulati A; Adekoya P; Kaye AM; Jones MR
    Curr Pain Headache Rep; 2021 Mar; 25(4):23. PubMed ID: 33693999
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adjunctive memantine for opioid use disorder treatment: A systematic review.
    Elias AM; Pepin MJ; Brown JN
    J Subst Abuse Treat; 2019 Dec; 107():38-43. PubMed ID: 31757263
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Naltrexone implant treatment for buprenorphine dependence--Mauritian case series.
    Jhugroo A; Ellayah D; Norman A; Hulse G
    J Psychopharmacol; 2014 Aug; 28(8):800-3. PubMed ID: 24695742
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Naltrexone and opiate substitutive treatment].
    Dupouy J; Poutrain JC; Lapeyre-Mestre M
    Therapie; 2011; 66(6):549-52. PubMed ID: 22691393
    [No Abstract]   [Full Text] [Related]  

  • 32. Effects of medication-assisted treatment on mortality among opioids users: a systematic review and meta-analysis.
    Ma J; Bao YP; Wang RJ; Su MF; Liu MX; Li JQ; Degenhardt L; Farrell M; Blow FC; Ilgen M; Shi J; Lu L
    Mol Psychiatry; 2019 Dec; 24(12):1868-1883. PubMed ID: 29934549
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CE: Acute Pain Management for People with Opioid Use Disorder.
    Broglio K; Matzo M
    Am J Nurs; 2018 Oct; 118(10):30-38. PubMed ID: 30211703
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Healthcare utilization and costs associated with treatment for opioid dependence.
    Shah A; Duncan M; Atreja N; Tai KS; Gore M
    J Med Econ; 2018 Apr; 21(4):406-415. PubMed ID: 29320915
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association of Medication-Assisted Therapy with New Onset of Cardiac Arrhythmia in Patients Diagnosed with Opioid Use Disorders.
    Raji MA; Priyadarshni S; Yu X; Digbeu B; Kuo YF
    Am J Med; 2022 Jul; 135(7):864-870.e3. PubMed ID: 35139325
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail.
    Velasquez M; Flannery M; Badolato R; Vittitow A; McDonald RD; Tofighi B; Garment AR; Giftos J; Lee JD
    Addict Sci Clin Pract; 2019 Oct; 14(1):37. PubMed ID: 31570100
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Age related medication for addiction treatment (MAT) use for opioid use disorder among Medicaid-insured patients in New York.
    Neighbors CJ; Choi S; Healy S; Yerneni R; Sun T; Shapoval L
    Subst Abuse Treat Prev Policy; 2019 Jun; 14(1):28. PubMed ID: 31238952
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Medication-assisted therapy for opioid-dependent incarcerated populations in New Mexico: statewide efforts to increase access.
    Trigg BG; Dickman SL
    Subst Abus; 2012; 33(1):76-84. PubMed ID: 22263716
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Challenges and Opportunities for the Use of Medications to Treat Opioid Addiction in the United States and Other Nations of the World.
    Parrino MW; Maremmani AG; Samuels PN; Maremmani I
    J Addict Dis; 2015; 34(2-3):255-62. PubMed ID: 26110357
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Medication-assisted treatment in criminal justice agencies affiliated with the criminal justice-drug abuse treatment studies (CJ-DATS): availability, barriers, and intentions.
    Friedmann PD; Hoskinson R; Gordon M; Schwartz R; Kinlock T; Knight K; Flynn PM; Welsh WN; Stein LA; Sacks S; O'Connell DJ; Knudsen HK; Shafer MS; Hall E; Frisman LK;
    Subst Abus; 2012; 33(1):9-18. PubMed ID: 22263709
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.